血友病实验室检测:因子与非因子替代治疗对凝血试验的影响
本文综述了延长半衰期(EHL)重组凝血因子和新型非因子替代治疗(如艾美珠单抗)对血友病实验室检测的挑战。EHL因子结构异质导致不同一阶段法间及一阶段法与显色法间活性水平差异大。文章探讨了诊断难点并考虑接受这些治疗患者的最佳诊断路径。
要点
- EHL因子在不同一阶段法间及与显色法间活性差异大,需注意方法学选择。
- 非因子治疗如艾美珠单抗干扰常规凝血试验解读,需标准化监测。
- 准确诊断方案是实现个体化治疗、减轻负担和提高生活质量的前提。
核心结论
- EHL重组因子和新型非因子治疗给血友病凝血监测带来标准化不足和结果误读风险。
研究设计与样本
- 综述性文章,检索范围未明确报告。
主要发现
- EHL重组因子结构及作用方式异质,不同一阶段法间及一阶段法与显色法间活性水平差异大。
- 人源性FVIII/FIX及全长重组产品在一阶段法和显色法中表现良好。
- 非因子治疗如艾美珠单抗的监测缺乏标准化方法。
关键数值与推荐
- 血友病确诊依赖功能凝血试验证明FVIII(血友病A)或FIX(血友病B)缺乏。
- 最常用试验基于活化部分凝血活酶时间,采用一阶段或两阶段法。
临床怎么用
- 接受EHL因子或非因子治疗的患者应选择适宜凝血试验方法并谨慎解读结果。
- 建议遵循血友病实验室诊断的阶梯式方法。
局限性
- 原文未明确报告综述检索范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The advent of extended half-life (EHL) recombinant clotting factors and innovative non-factor replacement therapeutics, such as emicizumab, offers several advantages over existing products for the prophylactic treatment of people living with hemophilia (PwH). These include low annual bleeding rates with less frequent dosing, higher trough plasma concentrations, and a more convenient route of administration. However, increasing use of these therapies poses challenges to clinicians and coagulation laboratories due to the lack of standardized assays for monitoring of hemostatic parameters, and the potential for misinterpretation of test results, which may jeopardize patient safety. Definitive diagnosis of hemophilia and treatment monitoring is reliant on demonstrating factor VIII (FVIII; hemophilia A) or factor IX (FIX; hemophilia B) deficiency using a functional coagulation assay. The most frequently used assays are based on activated partial thromboplastin time, using a one-stage or two-stage process. While one-stage and chromogenic assays have performed well with human-derived FVIII and FIX and full-length recombinant products, EHL recombinant factors are heterogeneous in structure and mode of action and therefore show wide variation in activity levels between different one-stage assays, and between one-stage and chromogenic assays. In the context of the recommended stepwise approach for laboratory diagnosis of hemophilia, we examine the diagnostic challenges associated with the use of EHL factors and novel non-factor therapeutics and consider the optimal diagnostic approach in PwH who are receiving these treatments. Ultimately, accurate diagnostic solutions are a prerequisite for personalized therapy to minimize treatment burden and improve quality of life in PwH.
引用
- Peyvandi F, Kenet G, Pekrul I, et al. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays. J Thromb Haemost. 2020. PMID: 32115865. doi:10.1111/jth.14784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。